Opioid Overprescribing: Can Physician Education Reverse It?
North Carolina county reports success in lowering opioid scrips during FDA public meeting on labeling for chronic pain, but little concrete data exists about what methods could be used to change doctor behavior.
You may also be interested in...
FDA will hold two-day public meeting to get stakeholder input on how to design and conduct studies on serious risks of extended-release/long-acting opioids.
Supporters of narrowing opioid drugs’ non-cancer pain indication tell FDA that pain patients often suffer the consequences of addiction and misuse.
REMS assessment schedule for the long-acting/extended release opioid products reflects the large number of drugs, prescribers and patients involved in the risk management program and the time needed to put all its components in place.